Point Vision acquired a controlling stake in Refract SAS, the parent company of Clinique de la Vision. This acquisition allows Point Vision to integrate a leading refractive surgery capability into its vast consultation network. The target retains its identity and organization, but a medical advisory committee will be established to harmonize governance. This build-up follows the roadmap set by Ares Management (majority owner since 2021) to expand the group's medical offering.

This transaction is part of the Healthcare & Pharma industry, which currently tracks an average EBITDA multiple of 13.4x since the beginning of 2026, 1.2% decrease compared to 2025. This data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.